« Aileron Reports Some Stapled Peptide Results |
| An HIV Structure Breakthrough? Or "Complete Rubbish"? »
August 15, 2013
Mannkind's Latest Data
I haven't written much about Mannkind recently. This has been a long, long, expensive saga to develop an inhaled-insulin delivery system (Afrezza), which is an idea that all by itself has seems to have swallowed several billion dollars and never given anything back yet. (That link above will send you to some of the story, and this one will tell you something about the disastrous failure of the only inhaled insulin to reach the market so far).
In 2011, Mannkind looked as if they were circling the drain. But (as has been the case many times before), more money was heaved into what might still turn out to be an incinerator, and they kept going. Just in the last few days, they've released another batch of Phase III data, which looked positive. You can see from the year-to-date stock chart that people have been anticipating this, which might account for the way that MNKD hasn't exactly taken off on the news. The stocked jumped at the open yesterday, then spent the rest of the day wandering down, and opened today right back where it was before the news came out.
People might be worried about possible effects on lung function, which show up in the data (FEV1 as well as a side effect of coughing). But there are potentially even bigger concerns in the number for HbA1c and fasting glucose. A closer look at the data shows that Mannkind's product may not have clearly established itself versus the injected-insulin competition. As that FiercePharma story says, this might not keep the product from being approved, but it could give it a rough time in the marketplace (and give Mannkind a rough time finding a big partner).
I wonder if there are any investors - other than Al Mann - who have stuck with this company all the way? If so, I wonder what effect that's had on their well-being? It has been a long, bizarre ride, and no one knows how many more curves and washed-out bridges might still be out there.
+ TrackBacks (0) | Category: Clinical Trials | Diabetes and Obesity
POST A COMMENT
- RELATED ENTRIES
- The Antibiotic Gap: It's All of the Above
- Phenotypic Assays in Cancer Drug Discovery
- Neratinib Comes Through For Puma
- How Many Biopharma Employees Would Rather Be Working Somewhere Else?
- The Broad Gets $650 Million For Psychiatric Research
- Put Them in Cells and Find Out
- The Hep C Field Gets Nastier By the Minute
- Allergan Twists and Turns